Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq:UTMD) reports changes in measures of financial performance for First Quarter (1Q) 2007 compared to 1Q 2006, as follows: Sales n/c Gross Profits ( 2%) Operating P

City, Utah - Utah Medical Products, Inc. (Nasdaq:UTMD) reports changes in

measures of financial performance for First Quarter (1Q) 2007 compared to

to 1Q 2006, 1Q 2007 gross profits declined 2% even though overall sales were

slightly higher because of a mix shift in distribution channels. International

sales at wholesale prices were up 20%, while domestic sales at retail prices

were down 5%. Operating profits were up 2% because operating expenses were

$130,000 lower as a result of lower litigation expenses and lower sales expenses

when selling through international distributors. Also, option compensation

expense included in G&A expenses in 1Q 2007 was $19,137 compared to $42,906

EBT were 2% lower because UTMD realized $212,000 in capital gains when

liquidating investment holdings in 1Q 2006, which did not recur in 1Q 2007.

income was 4% lower because of the lower EBT together with a higher income

provision rate, 35.0% in 1Q 2007 compared to 33.2% in 1Q 2006. The increased

rate resulted primarily from IRS discontinuance of the ETI deduction

(extraterritorial income exclusion). EPS declined less than net income because

diluted shares used to calculate EPS declined from 4,069,630 in 1Q 2006 to

4,015,955 in 1Q 2007 as a result of continuing share repurchases.

2007, UTMD achieved a consolidated gross profit margin (GPM) of 55.3% and

profit margin of 27.3%. In 1Q 2006, those respective profit margins were

and 28.7%. Although lower than the prior year, these 1Q 2007 margins remain

within management's targets.

1Q 2007 sales to 1Q 2006 sales in product categories, gynecology/ electrosurgery

product sales were up 9%, blood pressure monitoring/ components sales were

4%, neonatal product sales were down 1%, and obstetrics product sales were

6%. Trade shipments from UTMD Ireland were up 9% in EURO terms, but 19% in

Dollar (USD) terms because of a weaker USD. Because UTMD manufactures about

of its products sold overseas in Ireland, a weaker USD also contributes to

balance sheet remained strong. Please note that UTMD has classified $441,000

from the (Ireland) Note Payable into Current Liabilities because this amount

principal in current USD terms is due to be repaid within the next year.

to December 31, 2006, the entire remaining balance of the Note was classified

Liabilities below Current Liabilities on the Balance Sheet. This

reclassification reduces the Current Ratio as it was reported in prior press

releases since 4Q 2005.

to December 31, 2006, cash and investments increased about $0.6 million even

though inventories and receivables also increased $0.7 million, which consumes

operating cash. Stockholders' Equity increased $0.7 million even though

dividends and share repurchases, which reduce Stockholders' Equity, totaled $1.4

million. The increase in 1Q 2007 accrued liabilities resulted from the fact

in the 1Q unlike other calendar quarters, estimated income tax payments are

after the end of the quarter. Also unlike 1Q 2007, in 1Q 2006 accrued income

taxes from EBT were offset by a much larger than usual tax benefit resulting

from option exercises. Looking forward, the Company expects accrued liabilities

more consistent with prior quarters.

ratios, all of which meet management objectives, follow:

ROE (before payment of dividends) = 21%

dilution from unexercised option shares added to actual weighted average

outstanding shares for purposes of calculating eps was 74,500 in 1Q 2007

compared to 117,300 in 1Q 2006. The actual number of outstanding shares at

end of 1Q 2007 was 3,946,400 which included 1Q employee and outside director

option exercises of 25,900 shares and 1Q share repurchases of 16,900. The

average price paid by the Company to repurchase shares in the open market

1Q 2007 was $32.18 including commissions. The total number of outstanding

unexercised options at March 31, 2007 was about 201,500 shares at an average

exercise price of $20.33/ share, including shares awarded but not vested.

compares to 280,300 option shares outstanding at the end of 1Q 2006.

factors that could cause results to differ materially in future quarters

clinical acceptance of products, timing of regulatory approval of new products,

regulatory intervention in current operations, distribution limits by

anticompetitive hospital administrative agreements, the Company's ability to

efficiently manufacture, market, and sell its products, among other factors

have been outlined in UTMD=s

disclosure filings with the SEC. The SEC Form 10-Q for 1Q 2007 will be filed

with the SEC by May 10.

Medical Products, Inc., with particular interest in health care for women

their babies, develops, manufactures, assembles and markets a broad range

disposable and reusable specialty medical devices designed for better health

outcomes for patients and their care-providers. For more information about

Medical Products, Inc., visit UTMD=s

Medical Products, Inc.

STATEMENT, First Quarter ended March 31 (in thousands except earnings per